EXACT Historical Cash Flow
| EXAS Stock | USD 48.36 2.10 4.16% |
Analysis of EXACT Sciences cash flow over time is an excellent tool to project EXACT Sciences future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Cashflows From Financing Activities of 14.4 M or Depreciation of 225.6 M as it is a great indicator of EXACT Sciences ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining EXACT Sciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether EXACT Sciences is a good buy for the upcoming year.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in EXACT Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. About EXACT Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in EXACT balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which EXACT's non-liquid assets can be easily converted into cash.
EXACT Sciences Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by EXACT Sciences to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of EXACT Sciences operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from EXACT Sciences' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into EXACT Sciences current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in EXACT Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more information on how to buy EXACT Stock please use our How to Invest in EXACT Sciences guide.At this time, EXACT Sciences' Cash Flows Other Operating is comparatively stable compared to the past year. Change Receivables is likely to gain to about 73.8 M in 2025, despite the fact that Change In Working Capital is likely to grow to (53.2 M).
EXACT Sciences cash flow statement Correlations
Click cells to compare fundamentals
EXACT Sciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
EXACT Sciences cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 1.3B | (1.2B) | (73.0M) | 366.9M | (3.0M) | (2.9M) | |
| Free Cash Flow | 72.1M | (238.0M) | (438.0M) | 31.9M | 74.5M | 78.3M | |
| Change In Working Capital | (42.7M) | 111.1M | (26.4M) | (342K) | (56.0M) | (53.2M) | |
| Begin Period Cash Flow | 177.5M | 1.5B | 315.8M | 242.8M | 609.7M | 640.2M | |
| Other Cashflows From Financing Activities | 1.2B | 32.2M | 26.5M | 21.8M | 15.1M | 14.4M | |
| Depreciation | 163.4M | 180.3M | 197.6M | 206.6M | 214.9M | 225.6M | |
| Other Non Cash Items | 721.3M | 202.0M | 33.8M | (76.4M) | 819.8M | 860.8M | |
| Capital Expenditures | 64.4M | 135.8M | 214.5M | 124.2M | 136.0M | 142.8M | |
| Total Cash From Operating Activities | 136.5M | (102.2M) | (223.6M) | 156.1M | 210.5M | 221.1M | |
| Net Income | (848.5M) | (595.6M) | (623.5M) | (204.1M) | (1.0B) | (977.4M) | |
| Total Cash From Financing Activities | 1.9B | 8.5M | 76.5M | 159.8M | 231.9M | 202.6M | |
| End Period Cash Flow | 1.5B | 315.8M | 242.8M | 609.7M | 606.6M | 637.0M | |
| Other Cashflows From Investing Activities | (418.5M) | (58.8M) | 24.5M | 16.3M | (225K) | (236.3K) | |
| Change To Liabilities | 3.5M | 55.2M | 169.8M | (52.2M) | (60.0M) | (57.0M) | |
| Sale Purchase Of Stock | 18.4M | 23.1M | 25.5M | 28.3M | 31.2M | 21.0M | |
| Stock Based Compensation | 152.9M | 339.2M | 206.8M | 231.3M | 214.9M | 225.6M | |
| Total Cashflows From Investing Activities | (702.0M) | (1.1B) | 74.1M | 49.7M | (442.2M) | (420.0M) | |
| Change To Inventory | (30.3M) | (9.2M) | (13.2M) | (7.7M) | (34.9M) | (33.2M) | |
| Investments | (219.2M) | (387.8M) | 278.8M | 49.7M | (442.2M) | (420.0M) | |
| Dividends Paid | 17.2M | 18.4M | 37.5M | 169.5M | 194.9M | 108.4M | |
| Cash And Cash Equivalents Changes | 17.1M | 1.3B | (1.2B) | (73.0M) | (65.7M) | (62.4M) | |
| Cash Flows Other Operating | (152.3M) | 113.2M | (129.5M) | 118.4M | 136.2M | 143.0M | |
| Change To Account Receivables | (100.5M) | 25.2M | 61.1M | (43.4M) | (46.3M) | (43.9M) | |
| Change To Netincome | 106.5M | 777.6M | 195.3M | 181.3M | 208.5M | 131.1M | |
| Net Borrowings | 236.4M | 975.5M | (23.7M) | 50M | 57.5M | 54.6M | |
| Change Receivables | (27.9M) | (100.5M) | 25.2M | 61.1M | 70.3M | 73.8M | |
| Change To Operating Activities | (10.0M) | 32.9M | (74.6M) | (22.1M) | (19.8M) | (18.9M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for EXACT Stock Analysis
When running EXACT Sciences' price analysis, check to measure EXACT Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EXACT Sciences is operating at the current time. Most of EXACT Sciences' value examination focuses on studying past and present price action to predict the probability of EXACT Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EXACT Sciences' price. Additionally, you may evaluate how the addition of EXACT Sciences to your portfolios can decrease your overall portfolio volatility.